Michael Moore, chairman, Oxford BioTherapeutics
pharmafile | January 11, 2010 | Appointment | Research and Development | Oxford Biotherapeutics, Piramed, appointment, research and development
Oxford BioTherapeutics (OBT) has appointed Dr Michael Moore non-executive chairman.
He joins the company following five years spent at UK biotech Piramed, where he was chief executive until its 2008 acquisition by Roche.
Prior to that he was chief scientific officer and research director at Xenova and has previously held senior academic positions at the Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK and the Brunel Institute of Cancer Genetics and Pharmacogenomics, where he is still professor associate.
Dr Moore commented: “I am delighted to join Oxford BioTherapeutics at this exciting time in the company’s development. I have been highly impressed by OBT’s scientific and commercial approach and am very pleased to join the other distinguished members of the OBT Board and management, as we work together to set the strategic framework for the company’s continued growth and success.”
OBT recently recruited a number of other senior industry leaders in the biologics field, including new chief operating officer Jim Cornett and chief scientific officer Mike Gresser.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






